Based on the theory that inhibition of PARP results in the overexpression of PD‐L1 via GSK3β inactivation,41 University of Kentucky have developed 3 small‐molecule hybrid inhibitors of PARP and PD‐L1,and these results suggest that the properties of conjugates on tumor cells were enhanced compared with single drug.42 Here, PARP1 is linked to neoplasm.